Celine Saade1, Bhaskar Ganti1, Michael Marmor2, K Bailey Freund3, R Theodore Smith1. 1. Department of Ophthalmology, New York University School of Medicine, New York, New York, USA. 2. Department of Population Health, New York University School of Medicine, New York, New York, USA Department of Environmental Medicine, New York University School of Medicine, New York, New York, USA Department of Medicine, New York University School of Medicine, New York, New York, USA. 3. Department of Ophthalmology, New York University School of Medicine, New York, New York, USA Department of Ophthalmology, Columbia University, New York, New York, USA Vitreous Retina Macula Consultants of New York, New York, New York, USA LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital, New York, New York, USA.
Abstract
AIM: To investigate the risk characteristics of the combined geographic atrophy (GA) and choroidal neovascularisation (CNV) phenotype of age-related macular degeneration (AMD) compared to GA or CNV. METHODS: Patients with advanced AMD were identified and divided into three groups using multimodal imaging: patients with GA in at least one eye, patients with CNV in at least one eye, and patients with simultaneous GA and CNV in at least one eye. Epidemiologic and clinical factors were gathered from patient questionnaires. Genotypes for age-related maculopathy susceptibility 2 (ARMS2) and complement factor H (CFH) were determined. RESULTS: 42 patients with GA or CNV, and 16 patients with combined GA/CNV were identified. Patients with the combined phenotype were older (86.4 vs 81.8 years, p=0.049), and had a higher prevalence of advanced AMD in the fellow eye (81.3% vs 31.0%, p<0.001). CFH and ARMS2 risk alleles were not associated with the combined phenotype. CONCLUSIONS: The combined GA/CNV phenotype has similar epidemiologic, clinical, and genetic features as GA and CNV, but occurs at an older age and is more associated with advanced AMD in the fellow eye, suggesting that all these phenotypes are part of the same spectrum of disease and that the combined phenotype represents an even more advanced form of AMD than either GA or CNV. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
AIM: To investigate the risk characteristics of the combined geographic atrophy (GA) and choroidal neovascularisation (CNV) phenotype of age-related macular degeneration (AMD) compared to GA or CNV. METHODS:Patients with advanced AMD were identified and divided into three groups using multimodal imaging: patients with GA in at least one eye, patients with CNV in at least one eye, and patients with simultaneous GA and CNV in at least one eye. Epidemiologic and clinical factors were gathered from patient questionnaires. Genotypes for age-related maculopathy susceptibility 2 (ARMS2) and complement factor H (CFH) were determined. RESULTS: 42 patients with GA or CNV, and 16 patients with combined GA/CNV were identified. Patients with the combined phenotype were older (86.4 vs 81.8 years, p=0.049), and had a higher prevalence of advanced AMD in the fellow eye (81.3% vs 31.0%, p<0.001). CFH and ARMS2 risk alleles were not associated with the combined phenotype. CONCLUSIONS: The combined GA/CNV phenotype has similar epidemiologic, clinical, and genetic features as GA and CNV, but occurs at an older age and is more associated with advanced AMD in the fellow eye, suggesting that all these phenotypes are part of the same spectrum of disease and that the combined phenotype represents an even more advanced form of AMD than either GA or CNV. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: W Smith; J Assink; R Klein; P Mitchell; C C Klaver; B E Klein; A Hofman; S Jensen; J J Wang; P T de Jong Journal: Ophthalmology Date: 2001-04 Impact factor: 12.079
Authors: Sandra C Tomany; Jie Jin Wang; Redmer Van Leeuwen; Ronald Klein; Paul Mitchell; Johannes R Vingerling; Barbara E K Klein; Wayne Smith; Paulus T V M De Jong Journal: Ophthalmology Date: 2004-07 Impact factor: 12.079
Authors: Daniela Ferrara; Rachel E Silver; Ricardo N Louzada; Eduardo A Novais; Giliann K Collins; Johanna M Seddon Journal: Invest Ophthalmol Vis Sci Date: 2017-07-01 Impact factor: 4.799
Authors: Omer Trivizki; Eric M Moult; Liang Wang; Prashanth Iyer; Yingying Shi; Giovanni Gregori; William Feuer; James G Fujimoto; Philip J Rosenfeld Journal: Invest Ophthalmol Vis Sci Date: 2022-01-03 Impact factor: 4.799